title: Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults.
abstract: 301 healthy adult volunteers were randomized to one of three treatment groups: inactivated hepatitis A vaccine alone; inactivated hepatitis A vaccine with immune globulin (Ig) concurrently; or Ig alone. The first two treatment groups received a second dose of hepatitis A vaccine at week 24. Anti-HAV was measured 4, 8, 12, 24 and 28 weeks after the primary immunization. When comparing subjects receiving inactivated hepatitis A vaccine alone to those receiving vaccine and Ig, the seropositivity rates were not significantly different at 4, 8, 12 and 28 weeks, but at week 24 the seropositivity rate was lower in the group receiving both vaccine and Ig compared to the group receiving vaccine alone (92.0% compared to 97.0%). At weeks 8, 12 and 24 the geometric mean titers (GMTs) were significantly lower for subjects receiving both vaccine and Ig. The GMTs were not significantly different after the second dose of vaccine. At all time points, the lower serum antibody concentrations observed in subjects receiving both inactivated hepatitis A vaccine and Ig were nevertheless substantially higher than the cutoff for assay seropositivity and much higher than after Ig alone; these differences are therefore clinically insignificant.
authors: Department of Pediatrics, Duke University Medical Center, Durham, NC 27704, USA. walte002@mc.duke.edu
authors: E B
authors: EB
authors: Walter
authors: R B
authors: RB
authors: Hornick
authors: G A
authors: GA
authors: Poland
authors: R
authors: R
authors: Tucker
authors: C L
authors: CL
authors: Bland
authors: D A
authors: DA
authors: Clements
authors: C C
authors: CC
authors: Rhamstine
authors: R M
authors: RM
authors: Jacobson
authors: L
authors: L
authors: Brown
authors: J O
authors: JO
authors: Gress
authors: K E
authors: KE
authors: Harris
authors: B L
authors: BL
authors: Wiens
authors: D R
authors: DR
authors: Nalin
mesh_terms: D000293:Adolescent; D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000096:biosynthesis; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage* / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D007136:Immunoglobulins; D014613:Vaccines, Attenuated; D014761:Viral Hepatitis Vaccines